Insider is taking readers' specific skin concerns to dermatologists to get tailored advice, whether you have normal, dry, oily, or combination skin.
Meet the Doctor Behind Martha Stewart’s Glowing Skin (and Hailey Bieber’s Skincare Line) Who Just Hit a $200 Million Milestone for Patients
Dr. Dhaval Bhanusali, an NYC-based dermatologist to stars like Martha Stewart, just hit a $200 million milestone with his company, Skin Medicinals.
FDA OKs anti-wrinkle drug, a longer-lasting Botox competitor
The Food and Drug Administration (FDA) on Thursday approved the anti-wrinkle injection Daxxify, setting up competition for Botox, which has dominated the market for two decades. Manufacturer Revance ...
FDA Approves Botox Competitor That Lasts Longer
People wanting to keep wrinkles at bay will soon have a new option now that the U.S. Food and Drug Administration has approved the first competitor for Botox in decades. Daxxify, made by Revance ...
9 Of The Best TikTok Skin Care Influencers You Can Actually Trust
Most TikTok skinfluencers mean well. In fact, they often drive home important messages. “They do a wonderful job of emphasizing the importance of caring for your skin, sun protection and establishing ...
Chinese Face Mask Giant Syoung Group Invests in Skincare Startup Dermdoc
The seed round funding was announced on Dermdoc parent company Songyang’s official Wechat account. The investment in Dermdoc underscroes Syoung Group’s ambition in the niche skincare space. Syoung ...
‘I’m a Dermatologist, and This Is the One In-Office Treatment I’m Doing To Reset My Summer Skin Damage’
After three months of fun in the sun, this is the post-summer skin treatment a dermatologist swears by for reversing damage.
Botox rival can be ‘more broadly used’ in therapeutics: Revance CEO
Revance CEO Mark Foley joins Yahoo Finance Live to discuss the therapeutic company's anti-wrinkle Daxxify treatment, its multi-use purposes, and its competition with traditional Botox injections.
Revance Shares Jump 18% After FDA Approves Botox Rival Daxxify
The FDA approved Daxxify for temporary improvement of moderate to severe frown lines, Revance said in a Thursday morning statement. Shares of Revance climbed gradually Thursday afternoon, trading at ...